Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention - 15/08/11
Doi : 10.1016/j.ogc.2007.09.007
Francisco A.R. Garcia, MD, MPH a, ⁎ 
, Debbie Saslow, PhD b
, Debbie Saslow, PhD b a Obstetrics and Gynecology, Public Health and Mexican-American Studies, National Center of Excellence in Women’s Health, The University of Arizona, Tucson, AZ, USA
b Breast and Gynecologic Cancer, Cancer Control Science Department, The American Cancer Society, 250 William Street NW, Atlanta, GA 30303, USA
Corresponding author. Department of Obstetrics and Gynecology, Arizona Health Sciences Center, University Medical Center, 1501 North Campbell Avenue, 8th Floor, Tucson, AZ 85724-5078.Abstract |
Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.
Le texte complet de cet article est disponible en PDF.Plan
| This article is based in part on the American Cancer Society Guideline for human papillomavirus vaccine use to prevent cervical cancer and its precursors [124]. |
© 2007
Elsevier Inc. Tous droits réservés.
Vol 34 - N° 4
P. 761-781 - décembre 2007 Retour au numéro
Article précédent
- Cervical Cancer Prevention—Cervical Screening: Science in Evolution
- Mahboobeh Safaeian, Diane Solomon, Philip E. Castle
- Vulvo-Vaginal Cancers: Risks, Evaluation, Prevention and Early Detection
- Thinh H. Duong, Lisa C. Flowers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?